Research map: Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study

Back to the article

Papers in this map

  1. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications · Jack Satsangi · 2006 · 3217 citations · Cited by this paper
  2. Successful Treatment of Acrodermatitis Continua of Hallopeau With Upadacitinib · 2026 · Related
  3. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene · Richard H. Duerr · 2006 · 3063 citations · Cited by this paper
  4. Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report · 2026 · Related
  5. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain · Daniel J. Cua · 2003 · 2928 citations · Cited by this paper
  6. Functional Recovery After Multimodal Noninvasive Neuromodulation for Multimorbid PTSD, Bipolar Mania With Psychosis, and Psoriatic Arthritis · 2026 · Related
  7. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults · Christopher Andrew Lamb · 2019 · 2372 citations · Cited by this paper
  8. Blood Pressure Targets in Thoracic Aortic Disease: A Practical Comparison of ACC/AHA Guidance and Post-2024 European Guidelines · 2026 · Related
  9. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management · Fernando Gomollón · 2016 · 2099 citations · Cited by this paper
  10. Percutaneous Myocardial Revascularization in High- and Very High-Risk Non-ST Elevation Acute Coronary Syndromes: Real-World Insights From Two University Hospitals in Germany and Romania · 2026 · Related
  11. Predictability of the postoperative course of Crohn's disease · Paul Rutgeerts · 1990 · 1836 citations · Cited by this paper
  12. Outcomes With Peptide Receptor Radionuclide Therapy in Patients With Pheochromocytoma/Paraganglioma: A Center of Excellence Experience · 2026 · Related
  13. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD · Marco Daperno · 2004 · 1805 citations · Cited by this paper
  14. Abrocitinib as a Novel Therapeutic Option for Elastolytic Giant Cell Granuloma: A Case Report · 2026 · Related
  15. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials · Geert D’Haens · 2022 · 426 citations · Cited by this paper
  16. Salvage Therapy With Upadacitinib for Tofacitinib-Refractory Scarring Alopecia in an Asian Patient: Role of JAK1 Selective Inhibition · 2026 · Related
  17. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial · Marc Ferrante · 2022 · 342 citations · Cited by this paper
  18. Clozapine-Induced Pisa Syndrome During Lithium Treatment in a Patient With Bipolar Disorder and Methamphetamine Use Disorder · 2026 · Related
  19. Predicting the Crohnʼs disease activity index from the harvey-bradshaw index · William R. Best · 2006 · 309 citations · Cited by this paper
  20. Efficacy of Vebreltinib in Advanced Lung Adenocarcinoma With c-MET Amplification · 2026 · Related
  21. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease · Laurent Peyrin‐Biroulet · 2024 · 193 citations · Cited by this paper
  22. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality · Raja Narayana Atreya · 2022 · 74 citations · Cited by this paper
  23. Anti‐IL‐23 and Anti‐IL‐17 Biologic Agents for the Treatment of Immune‐Mediated Inflammatory Conditions · Jillian Frieder · 2017 · 73 citations · Cited by this paper
  24. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results · Tamer Atef Gheita · 2014 · 66 citations · Cited by this paper
  25. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system · Yamin Shu · 2023 · 46 citations · Cited by this paper
  26. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study · Dahham Alsoud · 2023 · 37 citations · Cited by this paper
  27. Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study · Mathurin Fuméry · 2024 · 31 citations · Cited by this paper
  28. Risankizumab Effectiveness and Safety in Crohn’s Disease: Real-world Data From a Large Tertiary Center · Adar Zinger · 2023 · 23 citations · Cited by this paper
  29. Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease · Adar Zinger · 2024 · 18 citations · Cited by this paper
  30. A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease · Amanda M. Johnson · 2025 · 17 citations · Cited by this paper
  31. Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium · Andres J. Yarur · 2024 · 12 citations · Cited by this paper
  32. Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data · Amanda M. Johnson · 2023 · 11 citations · Cited by this paper
  33. Long-Term Effectiveness and Safety of Ustekinumab in Crohn’s Disease: Results from a Large Real-Life Cohort Study · Giammarco Mocci · 2024 · 10 citations · Cited by this paper
  34. Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study · Maja Graves Rosenkilde Larsen · 2024 · 9 citations · Cited by this paper
  35. Endoscopy in Inflammatory Bowel Disease · Joëlle St‐Pierre · 2024 · 5 citations · Cited by this paper
  36. The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases · Fabio Salvatore Macaluso · 2024 · 5 citations · Cited by this paper
  37. Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease · Maryam A Alahmad · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)